|
 If the results are conclusive, the two drugmakers hope to see the
vaccine approved by the fourth quarter after having initially
targeted the first half of this year.
The move comes after the drugmakers in December said their vaccine
would be delayed after clinical trials showed an insufficient immune
response in older people.
The new trial will aim at evaluating the safety, tolerability and
immune response of the vaccine in 720 healthy adults across the
United States, Honduras and Panama, the companies said.
[to top of second column] |
 Sanofi and GSK's candidate uses
the same recombinant protein-based technology as
one of Sanofi's seasonal influenza vaccines. It
will be coupled with an adjuvant, a substance
that acts as a booster to the shot, made by GSK.
The study will test two injections given 21 days
apart.
(Reporting by Pushkala Aripaka in Bengaluru and
Matthias Blamont in Paris; editing by Jason
Neely)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
